Charles River Laboratories International, Inc. (CRL)
Company Info
| ISIN | US1598641074 |
|---|---|
| CUSIP | 159864107 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| IPO Date | Jun 23, 2000 |
Highlights
| Market Cap | $11.29B |
|---|---|
| EPS (TTM) | $7.84 |
| PE Ratio | 27.54 |
| PEG Ratio | 2.84 |
| Total Revenue (TTM) | $4.06B |
| Gross Profit (TTM) | $1.37B |
| EBITDA (TTM) | $924.19M |
| Year Range | $176.48 - $275.00 |
| Target Price | $217.89 |
| Short % | 5.28% |
| Short Ratio | 3.17 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: CRL vs. VOO, CRL vs. DGX, CRL vs. ADSK, CRL vs. DHR, CRL vs. SPY, CRL vs. ILMN, CRL vs. XLV
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Charles River Laboratories International, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Charles River Laboratories International, Inc. had a return of -12.63% year-to-date (YTD) and 15.79% in the last 12 months. Over the past 10 years, Charles River Laboratories International, Inc. had an annualized return of 12.50%, outperforming the S&P 500 benchmark which had an annualized return of 11.39%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -12.63% | 25.48% |
| 1 month | 6.94% | 2.14% |
| 6 months | -11.19% | 12.76% |
| 1 year | 15.79% | 33.14% |
| 5 years (annualized) | 8.26% | 13.96% |
| 10 years (annualized) | 12.50% | 11.39% |
Monthly Returns
The table below presents the monthly returns of CRL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -8.51% | 17.53% | 6.59% | -15.48% | -8.98% | -0.89% | 18.16% | -18.99% | -0.39% | -9.34% | -12.63% | ||
| 2023 | 11.63% | -9.83% | -7.99% | -5.80% | 1.71% | 8.72% | -0.34% | -1.30% | -5.24% | -14.09% | 17.06% | 19.95% | 8.49% |
| 2022 | -12.48% | -11.71% | -2.47% | -14.95% | -3.08% | -8.59% | 17.09% | -18.08% | -4.12% | 7.85% | 7.69% | -4.67% | -42.17% |
| 2021 | 3.68% | 10.46% | 1.29% | 14.71% | 1.67% | 9.45% | 10.00% | 9.08% | -7.03% | 8.73% | -18.46% | 2.98% | 50.80% |
| 2020 | 1.19% | 0.64% | -18.87% | 14.63% | 24.19% | -2.96% | 14.13% | 10.03% | 3.43% | 0.55% | 3.00% | 6.54% | 63.56% |
| 2019 | 8.84% | 15.41% | 2.17% | -3.29% | -10.69% | 13.11% | -5.19% | -2.48% | 0.89% | -1.81% | 11.75% | 5.17% | 34.97% |
| 2018 | -3.66% | 1.11% | 0.12% | -2.39% | 3.20% | 4.41% | 10.73% | -0.64% | 8.93% | -9.45% | 10.70% | -16.07% | 3.41% |
| 2017 | 6.05% | 7.64% | 3.43% | -0.28% | 2.62% | 9.89% | -2.92% | 10.79% | -0.72% | 7.66% | -10.40% | 5.04% | 43.65% |
| 2016 | -7.66% | -1.08% | 3.42% | 4.39% | 8.40% | -4.06% | 6.66% | -5.37% | 0.16% | -8.95% | -6.30% | 7.16% | -5.22% |
| 2015 | 8.97% | 10.56% | 3.42% | -12.78% | 4.60% | -2.76% | 10.35% | -11.25% | -7.80% | 2.71% | 17.37% | 4.99% | 26.32% |
| 2014 | 6.58% | 5.09% | 1.57% | -10.97% | -0.26% | -0.11% | 1.29% | 9.02% | 1.08% | 5.72% | 2.52% | -1.71% | 19.98% |
| 2013 | 10.27% | -1.40% | 8.66% | -1.76% | -0.41% | -5.26% | 10.99% | 1.12% | 0.46% | 6.38% | 6.02% | 1.67% | 41.55% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CRL is 54, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Charles River Laboratories International, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Charles River Laboratories International, Inc. was 69.81%, occurring on Nov 20, 2008. Recovery took 1545 trading sessions.
The current Charles River Laboratories International, Inc. drawdown is 54.93%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -69.81% | Aug 20, 2008 | 66 | Nov 20, 2008 | 1545 | Jan 13, 2015 | 1611 |
| -64.1% | Sep 27, 2021 | 527 | Oct 30, 2023 | — | — | — |
| -47.06% | Oct 2, 2000 | 111 | Mar 12, 2001 | 78 | Jul 2, 2001 | 189 |
| -44.54% | Feb 20, 2020 | 20 | Mar 18, 2020 | 50 | May 29, 2020 | 70 |
| -39.6% | Oct 24, 2002 | 118 | Apr 14, 2003 | 209 | Feb 11, 2004 | 327 |
Volatility
Volatility Chart
The current Charles River Laboratories International, Inc. volatility is 16.39%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Charles River Laboratories International, Inc. compared to its peers in the Diagnostics & Research industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for CRL in comparison to other companies of the Diagnostics & Research industry. Currently, CRL has a PE value of 27.5. This PE ratio falls in the average range for the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for CRL in comparison to other companies of the Diagnostics & Research industry. Currently, CRL has a PEG value of 2.8. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Charles River Laboratories International, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |